The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.
Proctor
S J
SJ
Northern Institute of Cancer Research, Academic Haematology, Medical School, Newcastle University. Electronic address: s.j.proctor@ncl.ac.uk.
Lennard
A L
AL
Department of Haematology.
Jackson
G H
GH
Department of Haematology.
Jones
G L
GL
Department of Haematology.
Lewis
J
J
Northern Centre for Cancer Treatment, Newcastle NHS Hospital Foundation Trust.
Wilkinson
J
J
Institute of Health and Society, Newcastle University.
White
J
J
Scotland and Newcastle Lymphoma Group, Academic Haematology, Medical School, Newcastle University, Newcastle upon Tyne.
Sieniawski
M
M
Northern Institute of Cancer Research, Academic Haematology, Medical School, Newcastle University.
McKay
P
P
Department of Haematology, Gartnavel General Hospital, Glasgow.
Culligan
D
D
Department of Haematology, Ward 16, Anchor Unit, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.
Lucraft
H H
HH
Northern Centre for Cancer Treatment, Newcastle NHS Hospital Foundation Trust.
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002699:Chlorambucil / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care; D017060:Patient Satisfaction; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors
D002699:Chlorambucil; D005047:Etoposide; D008130:Lomustine; D011239:Prednisolone